X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2949) 2949
programmed cell death 1 receptor - antagonists & inhibitors (2033) 2033
animals (1720) 1720
immunotherapy (1246) 1246
apoptosis (1240) 1240
oncology (1215) 1215
female (979) 979
programmed cell-death (975) 975
male (928) 928
cancer (919) 919
mice (772) 772
programmed cell death 1 receptor - immunology (733) 733
b7-h1 antigen - antagonists & inhibitors (700) 700
immunology (633) 633
nivolumab (603) 603
melanoma (586) 586
cell biology (567) 567
middle aged (546) 546
antibodies, monoclonal - therapeutic use (539) 539
ctla-4 antigen - antagonists & inhibitors (532) 532
aged (494) 494
pd-1 (489) 489
cell death (485) 485
immunotherapy - methods (484) 484
tumors (481) 481
antineoplastic agents - therapeutic use (474) 474
lymphocytes (460) 460
biochemistry & molecular biology (457) 457
expression (450) 450
ipilimumab (441) 441
programmed cell death 1 receptor - metabolism (441) 441
treatment outcome (418) 418
antineoplastic agents, immunological - therapeutic use (412) 412
pembrolizumab (395) 395
pd-1 protein (389) 389
chemotherapy (386) 386
care and treatment (377) 377
research (371) 371
immune checkpoint (365) 365
adult (361) 361
neoplasms - immunology (356) 356
signal transduction (342) 342
melanoma - drug therapy (332) 332
neoplasms - drug therapy (325) 325
t cells (325) 325
lymphocytes t (322) 322
b7-h1 antigen - immunology (320) 320
apoptosis - drug effects (318) 318
proteins (313) 313
cell line, tumor (312) 312
metastasis (312) 312
ligands (304) 304
antibodies, monoclonal, humanized - therapeutic use (292) 292
therapy (292) 292
patients (284) 284
survival (282) 282
activation (279) 279
open-label (275) 275
lung neoplasms - drug therapy (272) 272
apoptosis - physiology (270) 270
health aspects (269) 269
analysis (267) 267
t-lymphocytes - immunology (264) 264
b7-h1 antigen - metabolism (263) 263
molecular targeted therapy (261) 261
antineoplastic agents - pharmacology (260) 260
cancer therapies (257) 257
t-cells (256) 256
safety (255) 255
mice, inbred c57bl (251) 251
gene expression (249) 249
neurosciences (249) 249
blockade (247) 247
pd-l1 (247) 247
ctla-4 antigen - immunology (245) 245
programmed cell death (241) 241
cells, cultured (236) 236
cd8-positive t-lymphocytes - immunology (231) 231
antigens (229) 229
mutation (228) 228
prognosis (226) 226
antineoplastic combined chemotherapy protocols - therapeutic use (225) 225
carcinoma, non-small-cell lung - drug therapy (225) 225
pd-l1 protein (225) 225
lung cancer (224) 224
immune system (223) 223
clinical trials (221) 221
antibodies, monoclonal - pharmacology (220) 220
rats (220) 220
aged, 80 and over (219) 219
neoplasms - therapy (213) 213
antineoplastic agents, immunological - adverse effects (211) 211
disease models, animal (211) 211
multidisciplinary sciences (210) 210
pd-1 blockade (210) 210
medicine, research & experimental (204) 204
antibodies, monoclonal - adverse effects (202) 202
clinical trials as topic (202) 202
melanoma - immunology (199) 199
immune response (198) 198
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3916) 3916
French (33) 33
Czech (12) 12
German (12) 12
Chinese (11) 11
Japanese (9) 9
Danish (3) 3
Italian (2) 2
Polish (2) 2
Portuguese (2) 2
Spanish (2) 2
Croatian (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of thoracic oncology, ISSN 1556-0864, 2015, Volume 10, Issue 6, pp. 910 - 923
Epidermal growth factor receptor (EGFR) mutation status was reported to be associated with programmed death-ligand 1 (PD-L1) expression... 
PD-L1 | NSCLC | PD-1 | EGFR | Tyrosine kinase inhibitors | LUNG | CELLS | B7-H1 EXPRESSION | DEATH-LIGAND 1 | MELANOMA | ONCOLOGY | PATHWAY | IMMUNOTHERAPY | RESPIRATORY SYSTEM | POOR-PROGNOSIS | GROWTH | INHIBITORS | Tumor Escape - drug effects | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Sequence Deletion | Up-Regulation | Exons | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Molecular Targeted Therapy | Receptor, Epidermal Growth Factor - metabolism | T-Lymphocytes - pathology | Lung Neoplasms - genetics | Receptor, Epidermal Growth Factor - immunology | Lung Neoplasms - enzymology | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Programmed Cell Death 1 Receptor - metabolism | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | Carcinoma, Non-Small-Cell Lung - immunology | B7-H1 Antigen - metabolism | Lung Neoplasms - immunology | Apoptosis - immunology | B7-H1 Antigen - antagonists & inhibitors | Interferon-gamma - immunology | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | T-Lymphocytes - immunology | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Programmed Cell Death 1 Receptor - immunology | Programmed Cell Death 1 Receptor - genetics | Interferon-gamma - biosynthesis
Journal Article
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2017, Volume 74, pp. 55 - 72
.... T-cell exhaustion, overexpression of caspase-8 and β-catenin, PD-1/PD-L1 gene amplification, MHC-I/II mutations... 
Hematology, Oncology and Palliative Medicine | Molecular biology | Clinical development | Immuno-oncology | Novel antibodies | OX40 | NATURAL-KILLER-CELLS | SOLID TUMORS | CD4(+) T-CELLS | CANCER-IMMUNOTHERAPY | LUNG-CANCER | THERAPY | NK CELLS | ONCOLOGY | PHASE-I TRIAL | MONOCLONAL-ANTIBODIES | T-Lymphocyte Subsets - immunology | Immunotherapy - methods | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | B7 Antigens - immunology | Inducible T-Cell Co-Stimulator Protein - agonists | Glucocorticoid-Induced TNFR-Related Protein - drug effects | OX40 Ligand - agonists | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | Lymphocyte Activation - immunology | Neoplasms - therapy | Immunity, Cellular - physiology | Killer Cells, Natural - immunology | Tumor Necrosis Factor Receptor Superfamily, Member 9 - agonists | Cytokines - immunology | T-Lymphocytes, Cytotoxic - immunology | Antibodies, Monoclonal, Humanized - therapeutic use | CD40 Antigens - agonists | Antigens, CD - drug effects | B7 Antigens - antagonists & inhibitors | B-Lymphocytes - immunology | Neoplasms - immunology | Major Histocompatibility Complex - immunology | CTLA-4 Antigen - antagonists & inhibitors | Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors | Receptors, KIR - antagonists & inhibitors | Drugs | Chemotherapy | Cell death | Immunotherapy | Monoclonal antibodies | Control systems | T cells | Cancer
Journal Article
by Liu, Y and Cheng, Y and Xu, Y and Wang, Z and Du, X and Li, C and Peng, J and Gao, L and Liang, X and Ma, C
Oncogene, ISSN 1476-5594, 2017, Volume 36, Issue 44, pp. 6143 - 6153
.... Here we show that programmed cell death protein 1 (PD-1), a well-known immune checkpoint of T cells, is highly expressed on peripheral and tumor-infiltrating NK... 
NATURAL-KILLER-CELLS | VIRUS | BIOCHEMISTRY & MOLECULAR BIOLOGY | LIGAND 1 EXPRESSION | CELL BIOLOGY | HEPATOCELLULAR-CARCINOMA | ONCOLOGY | GASTRIC-CANCER | IMMUNE-RESPONSES | GENETICS & HEREDITY | DYSFUNCTION | TUMOR MICROENVIRONMENT | T-CELLS | PD-1 EXPRESSION | Signal Transduction | Humans | Gene Expression Regulation, Neoplastic | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Gastrointestinal Neoplasms - therapy | B7-H1 Antigen - immunology | Gastrointestinal Neoplasms - immunology | Xenograft Model Antitumor Assays | Gastrointestinal Neoplasms - pathology | Animals | B7-H1 Antigen - antagonists & inhibitors | Immunotherapy | Killer Cells, Natural - immunology | Female | Cell Proliferation - drug effects | Killer Cells, Natural - drug effects | Mice | Programmed Cell Death 1 Receptor - immunology | Killer cells | Care and treatment | Chemotherapy | Usage | Monoclonal antibodies | Dosage and administration | Research | Digestive system diseases | Diagnosis | T cells | Apoptosis | Cancer | Lymphocyte receptors | Cell survival | PD-1 protein | Cytokines | Liver | Blocking antibodies | AKT protein | Lymphocytes T | Esophagus | 1-Phosphatidylinositol 3-kinase | Proteins | Immune checkpoint | Cell death | Medical prognosis | PD-L1 protein | Xenografts | Degranulation | Natural killer cells | Tumors | Index Medicus | Original
Journal Article
Clinical and experimental immunology, ISSN 0009-9104, 2013, Volume 172, Issue 3, pp. 500 - 506
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 2015, Volume 125, Issue 5, pp. 2046 - 2058
T cell Ig and ITIM domain (TIGIT) is an inhibitory receptor expressed by activated T cells, Tregs, and NI( cells... 
MEDICINE, RESEARCH & EXPERIMENTAL | ADHESION MOLECULE | LIGANDS | DNAM-1 | INHIBITORY RECEPTORS | CHRONIC VIRAL-INFECTION | NECTIN-2 CD112 | UP-REGULATION | PVR CD155 | EXPRESSION | POLIOVIRUS RECEPTOR CD155 | Up-Regulation | Receptors, Immunologic - physiology | Receptors, Virus - biosynthesis | Humans | Neoplasm Proteins - physiology | Gene Expression Regulation, Neoplastic | Neoplasm Proteins - antagonists & inhibitors | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Programmed Cell Death 1 Receptor - physiology | Receptors, Virus - genetics | Receptors, Immunologic - antagonists & inhibitors | Receptors, Immunologic - biosynthesis | Programmed Cell Death 1 Receptor - biosynthesis | CD8-Positive T-Lymphocytes - metabolism | Lymphocytes, Tumor-Infiltrating - metabolism | Interleukin-2 Receptor beta Subunit - genetics | Neoplasm Proteins - genetics | Antibodies, Monoclonal - immunology | Antigen-Presenting Cells - metabolism | Antigens, Neoplasm - immunology | Lymphocyte Activation | Neoplasm Proteins - biosynthesis | Antibodies, Monoclonal - pharmacology | Immunophenotyping | Interleukin-2 Receptor beta Subunit - biosynthesis | Melanoma - pathology | Antigen-Presenting Cells - immunology | Melanoma - immunology | Antigens, Differentiation, T-Lymphocyte - genetics | Cell Line, Tumor | T-Cell Antigen Receptor Specificity | Immunologic Memory | Antigens, Differentiation, T-Lymphocyte - biosynthesis | CD8-Positive T-Lymphocytes - immunology | Receptors, Immunologic - genetics | Programmed Cell Death 1 Receptor - genetics | Cytokines - biosynthesis | Lymphocytes, Tumor-Infiltrating - immunology | Oncology | Immunology | Dermatology | Therapeutics
Journal Article
Journal Article
Cancer discovery, ISSN 2159-8290, 2017, Volume 7, Issue 3, pp. 264 - 276
.... We have examined the evolving landscape of tumor neoantigens during the emergence of acquired resistance in patients with non-small cell lung cancer after initial response to immune checkpoint... 
METASTATIC MELANOMA | CTLA-4 BLOCKADE | ONCOLOGY | PD-1 BLOCKADE | COLORECTAL-CANCER | PANCREATIC-CANCER | COPY NUMBER | RESISTANCE | MUTATIONS | SEQUENCING DATA | TUMOR PURITY | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Ipilimumab - pharmacology | Immunotherapy | Ipilimumab - therapeutic use | Janus Kinase 1 - genetics | Adult | Female | Receptors, Antigen, T-Cell - immunology | Cell Cycle Checkpoints - immunology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Receptors, Antigen, T-Cell - metabolism | Antigens, Neoplasm - immunology | Carcinoma, Non-Small-Cell Lung - genetics | Antibodies, Monoclonal - pharmacology | Janus Kinase 2 - genetics | CTLA-4 Antigen - genetics | Drug Resistance, Neoplasm - immunology | Lung Neoplasms - therapy | CTLA-4 Antigen - immunology | Antineoplastic Agents, Immunological - pharmacology | Carcinoma, Non-Small-Cell Lung - immunology | Carcinoma, Non-Small-Cell Lung - therapy | Drug Resistance, Neoplasm - genetics | Lung Neoplasms - immunology | Antineoplastic Agents, Immunological - therapeutic use | Cell Cycle Checkpoints - drug effects | Receptors, Antigen, T-Cell - genetics | Mutation | Programmed Cell Death 1 Receptor - immunology | Programmed Cell Death 1 Receptor - genetics | Cohort Studies
Journal Article
PloS one, ISSN 1932-6203, 2013, Volume 8, Issue 1, p. e55818
...), expression of programmed death receptor ligand 1/programmed death receptor 1 (PD-L1/PD-1), arginase 1 and soluble CD25... 
INTERLEUKIN-2-RECEPTOR | B7-H1 PD-L1 | ARGINASE | TUMOR BURDEN | SAFETY | MULTIDISCIPLINARY SCIENCES | IMATINIB | ANTIBODY | PHASE-I | CANCER | CLINICAL-SIGNIFICANCE | Antigens, CD34 - metabolism | Humans | Middle Aged | Arginase - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Young Adult | Lymphocyte Activation - immunology | T-Lymphocytes - metabolism | Myeloid Cells - immunology | Adult | Female | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology | Interleukin-2 Receptor alpha Subunit - blood | Programmed Cell Death 1 Receptor - metabolism | Gene Expression Regulation, Leukemic | B7-H1 Antigen - metabolism | Interleukin-2 Receptor alpha Subunit - metabolism | Adolescent | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Myeloid Cells - metabolism | T-Lymphocytes - immunology | Aged | Programmed Cell Death 1 Receptor - genetics | Medical research | Care and treatment | Immunotherapy | Medicine, Experimental | Development and progression | Interferon | Chronic myeloid leukemia | T cells | Risk factors | Cancer | Cell proliferation | Disease | PD-1 protein | Laboratories | Leukemia | Science | Clinical trials | Risk | Arginase | Lymphocytes T | Kinases | Suppressor cells | Ethics | Immunology | Interleukin 2 | Lymphocytes | Cell cycle | CD25 antigen | Protein-tyrosine kinase | Immune system | Tyrosine | CD34 antigen | Myeloid cells | Cytokines | Hematology | Myeloid leukemia | Mortality | Blood banks | Patients | Studies | Pathology | Hospitals | Medical prognosis | PD-L1 protein | Stem cells | Ligands | Death | Lymphomas | Apoptosis
Journal Article